Literature DB >> 7840856

Natural history of humoral immunity to glutamic acid decarboxylase in non-obese diabetic (NOD) mice.

H J De Aizpurua1, M B French, N Chosich, L C Harrison.   

Abstract

Autoantibodies to glutamic acid decarboxylase (GAD) are present in humans before and after the onset of clinical insulin-dependent diabetes (IDD). The non-obese diabetic (NOD) mouse, a model of human IDD, develops mononuclear cell infiltration of the pancreatic islets ('insulitis') associated particularly in females with T cell-mediated destruction of the islet beta cells. In NOD mice of both sexes we detected serum antibodies to GAD (GAD Ab) that precipitate mouse brain GAD enzymatic activity. Antibodies in NOD sera also precipitate a M(r) 65,000 protein from Triton X-100 extracts of 35S-methionine-labelled NOD islets, identical in size to that precipitated by a monoclonal antibody to GAD. GAD Ab were not detected in other mouse strains. There were significant differences in the frequency, level and age at initial detection of GAD Ab between females of the NOD/Lt and NOD/WEHI lines, previously shown to have a higher and lower incidence of diabetes, respectively. Comparing NOD/Lt (n = 26) and NOD/WEHI (n = 20) females, in which diabetes occurred in 38% and 20% by 150 days, the frequency of elevated GAD Ab was 50 vs. 80%, the mean maximum GAD Ab level 21.1 vs. 30.6% and the mean age at which GAD Ab were first detected 94 vs. 45 days. No significant differences in these parameters were observed between male mice of either line. There was a significant negative correlation between the level of GAD Ab and the degree of insulitis in female mice from both lines. GAD Ab were not a prerequisite for the development of diabetes. In 7 of 10 female mice the onset of diabetes was preceded by a decrease of GAD Ab levels into the normal range. These findings indicate that, while GAD is a target of autoimmunity in the NOD mouse, GAD Ab do not necessarily correlate with the development of diabetes. Indeed, the difference between the two NOD lines and the inverse relationship with insulitis suggests that a strong humoral response to GAD may be associated with a less destructive pathology, as proposed in humans 'at-risk' for IDD.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7840856     DOI: 10.1006/jaut.1994.1049

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  6 in total

Review 1.  Immunomodulatory therapy to preserve pancreatic β-cell function in type 1 diabetes.

Authors:  Frank Waldron-Lynch; Kevan C Herold
Journal:  Nat Rev Drug Discov       Date:  2011-06       Impact factor: 84.694

2.  Cytokine regulation of glutamate decarboxylase biosynthesis in isolated rat islets of Langerhans.

Authors:  R S Schmidli; B E Faulkner-Jones; L C Harrison; R F James; H J DeAizpurua
Journal:  Biochem J       Date:  1996-08-01       Impact factor: 3.857

Review 3.  Antigen-based vaccination and prevention of type 1 diabetes.

Authors:  Leonard C Harrison; John M Wentworth; Yuxia Zhang; Esther Bandala-Sanchez; Ralph M Böhmer; Alana M Neale; Natalie L Stone; Gaetano Naselli; Julian J Bosco; Priscilla Auyeung; Maryam Rashidi; Petra Augstein; Grant Morahan
Journal:  Curr Diab Rep       Date:  2013-10       Impact factor: 4.810

Review 4.  Trials in type 1 diabetes: Antigen-specific therapies.

Authors:  Ken T Coppieters; Leonard C Harrison; Matthias G von Herrath
Journal:  Clin Immunol       Date:  2013-02-15       Impact factor: 3.969

5.  Discovery of native autoantigens via antigen surrogate technology: application to type 1 diabetes.

Authors:  Todd M Doran; Scott Simanski; Thomas Kodadek
Journal:  ACS Chem Biol       Date:  2014-12-17       Impact factor: 5.100

Review 6.  The importance of the Non Obese Diabetic (NOD) mouse model in autoimmune diabetes.

Authors:  James A Pearson; F Susan Wong; Li Wen
Journal:  J Autoimmun       Date:  2015-09-26       Impact factor: 7.094

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.